Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibrin formation is the process by which the soluble plasma protein fibrinogen is enzymatically cleaved by thrombin to produce insoluble fibrin monomers, which polymerize into a fibrous network forming the basis of a blood clot. This network entraps platelets and cells, contracts over time, and stabilizes the wound site. Fibrin plays essential roles in hemostasis, wound healing, and protection from infection, but its dysregulation can lead to bleeding disorders or pathological thrombosis. Promoting fibrin formation is not a direct target but a therapeutic strategy employed in conditions of excessive bleeding or impaired hemostasis, typically via agents that enhance thrombin activity or provide fibrinogen directly. In summary, "Fibrin formation promotion" should be replaced by "Fibrin" or "Fibrinogen" for structured record-keeping, and is not itself a molecular target but describes a vital physiological process.
For drugs that promote fibrin formation: Enhancing thrombin activity (thrombin activates fibrinogen to form fibrin); Direct fibrin application; Inhibition of natural anticoagulants to favor clot formation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin formation promotion (None commonly).